How Much Does Vardenafil (Levitra/Staxyn) Cost in Maryland in 2026?

Maryland Retail Pricing: Brand vs. Generic Vardenafil

The gap between brand-name Levitra and its generic equivalents remains wide. Bayer's list price for branded Levitra hovers around $350 per month in 2026, a figure that has changed little since the drug lost exclusivity. Generic vardenafil, by contrast, averages roughly $120 per month across Maryland retail pharmacies for a standard on-demand supply.

Prices vary by pharmacy. Large chains like CVS and Walgreens in Baltimore, Bethesda, and Annapolis tend to cluster near that $120 average, but independent pharmacies in smaller Maryland towns sometimes price 10 to 15 percent lower. Costco pharmacies (which do not require a membership for prescription purchases) often post some of the lowest per-tablet rates in the state. Staxyn, the orally disintegrating tablet formulation, generally costs more than standard vardenafil tablets because no generic equivalent for that specific formulation has reached the U.S. market.

Vardenafil earned FDA approval in 2003 as the second PDE5 inhibitor after sildenafil. In the key trial by Porst et al. (N=601), vardenafil 20 mg improved the International Index of Erectile Function (IIEF) erectile function domain score by 9.9 points over placebo (P<0.001), with 80% of intercourse attempts successful at the highest dose 1. That efficacy profile has kept the drug relevant even as newer competitors entered the market.

Maryland Medicaid Coverage for Vardenafil

Maryland Medicaid does cover vardenafil. Prior authorization is required. This means your prescriber must submit documentation to the state confirming a diagnosis of erectile dysfunction and, in most cases, demonstrating that the medication is medically necessary rather than purely elective.

The PA process in Maryland typically takes 24 to 72 hours for standard requests. Urgent requests can be processed faster. Maryland's Medicaid preferred drug list (PDL) groups PDE5 inhibitors together, and the specific tier placement of vardenafil relative to sildenafil or tadalafil can shift with each formulary update. If sildenafil is listed as the preferred agent (which is common given its lower cost), your provider may need to document why vardenafil is the appropriate choice. Reasons that generally satisfy PA criteria include intolerance to sildenafil side effects, inadequate response to sildenafil at maximum dose, or a clinical need for vardenafil's specific pharmacokinetic profile.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that PDE5 inhibitors are first-line pharmacotherapy for erectile dysfunction regardless of testosterone status, a position that supports PA approval when the clinical indication is documented. Maryland Medicaid enrollees who are also eligible for Medicare (dual-eligible beneficiaries) should be aware that Medicare Part D historically excluded erectile dysfunction drugs, though coverage policies have shifted in recent years. Check your specific plan formulary.

Private Insurance Coverage in Maryland

Most commercial insurance plans sold in Maryland cover generic vardenafil, though benefit designs vary. Quantity limits are common. A typical restriction allows 6 to 12 tablets per month, which aligns with on-demand use patterns described in the prescribing information.

CareFirst BlueCross BlueShield, the dominant insurer in the Maryland market, generally places generic vardenafil on Tier 2 or Tier 3 of its formularies. Copays at those tiers typically range from $20 to $60 per fill. Kaiser Permanente Mid-Atlantic plans may require step therapy through sildenafil before approving vardenafil. United Healthcare and Aetna plans sold through the Maryland Health Benefit Exchange follow similar patterns: generic PDE5 inhibitors are covered, but prior authorization or step therapy requirements are standard.

Employer-sponsored plans can be more variable. Some large Maryland employers (particularly federal agencies headquartered in the D.C. suburbs) offer generous prescription benefits that cover vardenafil with minimal restrictions. Others carve out erectile dysfunction medications entirely. The only way to know your specific coverage is to check your plan's formulary or call the number on your insurance card.

A 2024 analysis published in the Journal of Sexual Medicine found that out-of-pocket spending on PDE5 inhibitors dropped 42% between 2018 and 2023 as generic competition intensified across the class 2. Maryland patients with commercial insurance are direct beneficiaries of this trend.

Compounded Vardenafil in Maryland: Legality and Access

Compounded vardenafil is legal in Maryland when dispensed by a pharmacy operating under a valid 503A license. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare patient-specific prescriptions that differ from commercially available formulations in dose, combination, or delivery method.

Several 503A-licensed pharmacies in Maryland compound vardenafil. These pharmacies can prepare custom doses (for example, 15 mg if a patient responds poorly to 10 mg but experiences side effects at 20 mg), combination formulations that pair vardenafil with other agents, or sublingual troches for patients who prefer faster onset. Compounded medications are not FDA-approved, and patients should understand that compounded products do not undergo the same bioequivalence testing as manufactured generics.

The Maryland Board of Pharmacy oversees compounding pharmacies in the state. Pharmacies must hold a valid Maryland compounding permit and comply with USP <795> standards for non-sterile compounding. Patients can verify a pharmacy's license status through the Board's online lookup tool.

Pricing for compounded vardenafil varies significantly. Some telehealth platforms that partner with 503A pharmacies advertise combination ED formulations (vardenafil plus tadalafil, or vardenafil plus apomorphine) at prices competitive with or below retail generic pricing. The American Association of Clinical Endocrinology (AACE) guidelines do not specifically address compounded PDE5 inhibitors, but they do recommend that clinicians use FDA-approved products as first-line therapy when available.

Telehealth Prescribing of Vardenafil in Maryland

Maryland permits telehealth prescribing of vardenafil. The state's telehealth parity law, updated in 2021, requires insurers to cover telehealth visits at the same rate as in-person visits. This means a Maryland resident can receive a vardenafil prescription from a licensed telehealth provider without ever entering a brick-and-mortar clinic.

Several national telehealth platforms serve Maryland patients for erectile dysfunction. The typical workflow involves completing an online health questionnaire, having a synchronous video or audio consultation with a licensed prescriber, and receiving a prescription sent to a pharmacy of your choice. Some platforms bundle the consultation fee with the medication cost.

One practical advantage of telehealth for vardenafil prescriptions: refill management. Because vardenafil is used on demand rather than daily, patients sometimes go months between refills and then need a new prescription quickly. Telehealth platforms that maintain ongoing patient relationships can issue refills within hours rather than requiring a new office visit.

The FDA's prescribing information for vardenafil specifies that the drug is contraindicated with nitrate medications and alpha-blockers at certain doses. Any legitimate telehealth provider will screen for these interactions before prescribing. Be wary of platforms that skip the medical consultation entirely.

How to Pay Less for Vardenafil in Maryland

Multiple strategies can reduce out-of-pocket costs. Start with the most impactful.

Use a pharmacy discount card. GoodRx, RxSaver, and similar aggregators often show vardenafil prices 20 to 40% below the average retail cash price at Maryland pharmacies. These cards are free, require no insurance, and work at most chain pharmacies. Prices fluctuate weekly, so check before each fill.

Ask about manufacturer savings programs. Bayer has historically offered copay assistance cards for branded Levitra, though the value of these cards has diminished as generic uptake has grown. Generic manufacturers occasionally run promotional pricing through pharmacy partners.

Compare pharmacies aggressively. A 2023 study in JAMA Internal Medicine found that cash prices for the same generic drug varied by as much as 10-fold across pharmacies within a single metropolitan area 3. Baltimore is no exception. Checking three or four pharmacies before filling a vardenafil prescription can save $30 to $60 per month.

Consider 90-day fills. If your usage pattern is predictable, a 90-day supply typically costs less per tablet than three separate 30-day fills. Many Maryland pharmacies, including mail-order options through CareFirst and Kaiser, offer this.

Ask your prescriber about therapeutic alternatives. Sildenafil (generic Viagra) is the cheapest PDE5 inhibitor in virtually every pharmacy in Maryland, with cash prices sometimes falling below $1 per tablet. If you have not tried sildenafil, or if you tolerated it well in the past, switching could cut your cost by 50% or more. The American Urological Association's guideline on erectile dysfunction treats all PDE5 inhibitors as clinically equivalent first-line options, noting that choice among them should be based on patient preference, side-effect profile, and cost.

Vardenafil vs. Other PDE5 Inhibitors: Maryland Cost Comparison

Understanding where vardenafil fits in the broader PDE5 inhibitor market helps Maryland patients make informed decisions.

Sildenafil (generic Viagra) is the least expensive option, averaging $30 to $60 per month in Maryland. Tadalafil (generic Cialis) falls in a similar range for on-demand use, though daily low-dose tadalafil (2.5 or 5 mg) can cost more due to higher tablet counts. Vardenafil at $120 per month occupies a middle tier. Avanafil (Stendra) remains the most expensive, with limited generic availability pushing prices above $200 per month.

The pharmacokinetic differences between these drugs are real but modest. Vardenafil's onset of action (approximately 30 to 60 minutes) and duration (4 to 5 hours) are similar to sildenafil. A meta-analysis by Yuan et al. (2013, N=82 trials) found no statistically significant differences in overall efficacy among PDE5 inhibitors when compared at optimal doses 4. Patient-level response does vary, though. Some men report better tolerability with vardenafil than sildenafil, particularly regarding visual disturbances and flushing, because vardenafil has higher selectivity for PDE5 over PDE6 5.

For Maryland patients on a budget, the rational approach is to trial sildenafil first (given its cost advantage), reserve vardenafil for cases where sildenafil causes unacceptable side effects or insufficient response, and consider tadalafil when the longer duration of action (up to 36 hours) offers a practical benefit.

What Maryland Patients Should Know About Vardenafil Safety

Vardenafil is well-tolerated in most men. The most common side effects in clinical trials were headache (15%), flushing (11%), rhinitis (9%), and dyspepsia (4%) 1. These are class effects shared by all PDE5 inhibitors.

The critical safety concern is the interaction with nitrate medications (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate). Combining vardenafil with any nitrate can cause severe, potentially fatal hypotension. This is an absolute contraindication. Maryland prescribers and pharmacists are required to screen for this interaction, but patients should proactively disclose all medications, including sublingual nitroglycerin kept for emergency use.

Vardenafil also carries a unique warning among PDE5 inhibitors regarding QT prolongation. The FDA label notes that vardenafil 10 mg produced a mean QTc increase of 8 milliseconds in healthy volunteers. Men with congenital long QT syndrome or those taking Class IA or Class III antiarrhythmic medications (quinidine, procainamide, amiodarone, sotalol) should not use vardenafil. This is a differentiating safety factor that may steer some patients toward sildenafil or tadalafil instead.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins (located in Baltimore, Maryland), has stated: "PDE5 inhibitor selection should be individualized based on the patient's comorbidity profile, concomitant medications, and anticipated frequency of sexual activity." This patient-centered framework applies directly to the cost conversation: the cheapest drug is not always the right drug, and the right drug at a price the patient cannot afford is functionally useless.

The CDC reports that approximately 30 million American men experience erectile dysfunction, with prevalence increasing sharply after age 40. Maryland's population of roughly 6.2 million includes an estimated 400,000 to 500,000 men affected by ED, many of whom are candidates for PDE5 inhibitor therapy.